Bindu Kanapuru

MedicineEconomics, Econometrics and FinanceBiochemistry, Genetics and Molecular BiologyMathematics

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 8 papers. Top paper: “FDA Approval Summary: Idecabtagene Vicleucel for Relapsed or Refractory Multiple Myeloma”.

FDA Approval Summary: Idecabtagene Vicleucel for Relapsed or Refractory Multiple Myeloma

Clinical Cancer Research(2022)10.1158/1078-0432.ccr-21-3803

N/A

2.6DataRank · unranked

94 citations

Bindu Kanapuru, Bindu George, Xue Lin, Zhenzhen Xu, Wilson W. Bryan +3 more

FDA Approval Summary: Belantamab Mafodotin for Patients with Relapsed or Refractory Multiple Myeloma

Clinical Cancer Research(2022)10.1158/1078-0432.ccr-22-0618

N/A

0DataRank · unranked

56 citations

Rachel Ershler, Bindu Kanapuru, Qing Xu, Guoxiang Shen, Liang Li +8 more

Extreme body mass index and survival in newly diagnosed multiple myeloma patients

Blood Cancer Journal(2023)10.1038/s41408-022-00782-7

N/A

0DataRank · unranked

23 citations

Karissa Whiting, Sean M. Devlin, Rachel Ershler, Bindu Kanapuru, David Jungpa Lee +14 more

Minimal Residual Disease Data in Hematologic Malignancy Drug Applications and Labeling: An FDA Perspective

Clinical Cancer Research(2023)10.1158/1078-0432.ccr-22-3579

N/A

0DataRank · unranked

11 citations

Maryam Sarraf Yazdy, Yvette L. Kasamon, Rachel Ershler, Emily Y. Jen, Bindu Kanapuru +7 more

FDA Approval Summary: Ciltacabtagene Autoleucel for Relapsed or Refractory Multiple Myeloma

Clinical Cancer Research(2024)10.1158/1078-0432.ccr-24-0378

N/A

0DataRank · unranked

42 citations

Megha Kaushal, Bindu George, Bindu Kanapuru, Marc R. Theoret, Kavita Natrajan

FDA Approval Summary: Teclistamab–A Bispecific CD3 T-Cell Engager for Patients with Relapsed or Refractory Multiple Myeloma

Clinical Cancer Research(2024)10.1158/1078-0432.ccr-24-1872

N/A

0DataRank · unranked

13 citations

Bindu Kanapuru, Jay Zhao, Lauren Price, Nan Zheng, Robyn Konicki +5 more

Roadmap to 2030 for Drug Evaluation in Older Adults

Clinical Pharmacology & Therapeutics(2021)10.1002/cpt.2452

N/A

0DataRank · unranked

70 citations

Janice B. Schwartz, Patricia W. Slattum, Sandra Lau, Daphne Guinn, Rajanikanth Madabushi +20 more

FDA Approval Summary: Idecabtagene Vicleucel for the Treatment of Triple-Class–Exposed, Relapsed or Refractory Multiple Myeloma

Clinical Cancer Research(2025)10.1158/1078-0432.ccr-24-4181

N/A

0DataRank · unranked

8 citations

Xue Lin, Zhenzhen Xu, Bindu Kanapuru, Marc R. Theoret, Robert Sokolic +2 more